The following government grants in the FederalGrants.com database contain the term housing in the listing.
Grants are sorted newest to oldest. Select a grant title to view the complete details, including information on who to contact and how to apply.
| Grant Title | CFDA | Funding Number |
| BRAIN Initiative: Promoting Equity Through BRAIN Technology Partnerships (R34 - Clinical Trials Not Allowed) |
93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867 |
RFA-NS-25-016 |
| Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) |
93.233, 93.837, 93.838, 93.839 |
RFA-HL-26-017 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) |
93.393, 93.394, 93.395, 93.396, 93.399 |
PAR-25-171 |
| Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed) |
93.855 |
RFA-AI-24-076 |
| Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional) |
93.242, 93.279 |
PAR-25-278 |
| Occupational Safety and Health Training Project Grants (T03) |
93.262 |
RFA-OH-25-003 |
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) |
93.399 |
PA-25-294 |
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) |
93.399 |
PA-25-295 |
| Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required) |
93.310 |
RFA-RM-24-008 |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) |
93.393 |
PAR-25-248 |
| Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) |
93.399 |
PAR-25-254 |
| Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required) |
93.213 |
PAR-25-274 |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) |
93.242 |
PAR-25-286 |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed) |
93.242 |
PAR-25-287 |
| NINR Resources and Related Research Projects in Firearm Injury Prevention (R24 Clinical Trial Not Allowed) |
93.313, 93.361 |
RFA-NR-25-002 |
| NEI Postbaccalaureate Opportunities in Vision Science (POVS) Research Education Program (R25 Clinical Trial Not Allowed) |
93.867 |
PAR-24-290 |
| Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required) |
93.213 |
PAR-25-268 |
| Limited Competition: NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinical Trial Not Allowed) |
93.279, 93.853 |
RFA-NS-25-027 |
| NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) |
93.213 |
PAR-25-267 |
| Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed) |
93.242, 93.279, 93.853 |
RFA-MH-26-111 |
| Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required) |
93.121, 93.273, 93.279, 93.307, 93.313, 93.399 |
PAR-26-001 |
| Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed) |
93.242, 93.279, 93.853 |
RFA-MH-26-110 |
| NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) |
93.279 |
PAR-25-261 |
| Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) |
93.242 |
PAR-25-034 |
| Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) |
93.242 |
PAR-25-035 |
| Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) |
93.394, 93.395 |
PAR-25-106 |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) |
93.121, 93.395, 93.396 |
PAR-25-107 |
| Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) |
93.172, 93.213, 93.242, 93.286, 93.313, 93.846, 93.853, 93.866, 93.867 |
PAS-25-190 |
| Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) |
93.242, 93.879 |
PAR-25-235 |
| Co-infection and Cancer (R01 Clinical Trial Not Allowed) |
93.393 |
PAR-25-082 |
| Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) |
93.393 |
PAR-25-186 |
| Co-infection and Cancer (R21 Clinical Trial Not Allowed) |
93.399 |
PAR-25-083 |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) |
93.398 |
PAR-25-135 |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) |
93.853 |
PAR-25-052 |
| FY25 IIJA/IRA Bureau of Land Management Oregon/Washington (ORWA) Aquatic Resource Management |
15.244 |
L25AS00088 |
| Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) |
93.279, 93.855 |
RFA-DA-26-034 |
| Biology of Bladder Cancer (R21 Clinical Trial Optional) |
93.393 |
PAR-25-128 |
| Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed) |
93.173, 93.350, 93.865 |
PAR-25-217 |
| Biology of Bladder Cancer (R01 Clinical Trial Optional) |
93.393, 93.396 |
PAR-25-129 |
| Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed) |
93.173, 93.242, 93.350, 93.865 |
PAR-25-220 |
Search Results 281-320 of 18477
[Prev] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 [Next] |
